Valion Bio, Inc.
VBIO Healthcare Biotechnology
Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023. In the quarter to June 2026, revenue grew 15.9%, EPS was flat and free cash flow fell 189.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow VBIO
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
12.65 | 2.00 | 3.40 | 3.52 | 12.98 | 1.04 | 2.31 |
Receivables |
— | 0.07 | 0.17 | 0.11 | 0.09 | 0.05 | 0.01 |
Inventory |
— | 0.32 | 0.76 | 0.86 | 0.43 | 0.24 | 0.48 |
Total current assets |
13.01 | 2.64 | 4.65 | 5.31 | 14.29 | 1.50 | 2.97 |
Property, Plant, Equpment (Net) |
12.64 | 0.00 | 0.12 | 0.01 | 0.01 | 0.02 | 0.03 |
Goodwill and Intangible Assets (Total) |
5.70 | — | — | — | — | — | — |
Long-term assets (Other) |
0.12 | — | 0.03 | 0.03 | 0.05 | 0.02 | 0.02 |
Total non-current assets |
18.60 | 0.17 | 0.51 | 0.57 | 0.75 | 0.03 | 0.05 |
Total Assets |
31.61 | 2.81 | 5.16 | 5.88 | 15.04 | 1.53 | 3.02 |
Notes Payable |
— | — | — | — | — | 0.04 | — |
Accounts Payable |
0.26 | 0.13 | 0.71 | 1.32 | 0.79 | 0.37 | 0.37 |
Other current liabilities |
— | — | — | — | — | 0.72 | 0.28 |
Total current liabilities |
0.65 | 0.27 | 1.40 | 1.88 | 1.22 | 1.28 | 0.65 |
Long Term Debt (Total) |
6.45 | — | — | 0.37 | 0.55 | 1.43 | — |
Non-current Liabilities (Other) |
0.34 | — | — | — | — | — | — |
Total non-current liabilities |
6.79 | — | 0.18 | 0.37 | 0.55 | 1.43 | — |
Total liabilities |
7.44 | 0.27 | 1.58 | 2.25 | 1.76 | 2.71 | 0.65 |
Additional Paid In Capital |
69.39 | 46.08 | 41.47 | 33.27 | 32.82 | 9.87 | 9.78 |
Preferred Stock (Total) |
7.37 | — | — | — | — | 0.00 | 0.00 |
Common Stock (Net) |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Retained Earnings |
(52.60) | (43.54) | (37.89) | (29.64) | (19.55) | (11.05) | (7.41) |
Common Equity (Total) |
16.80 | 2.54 | 3.58 | 3.63 | 13.27 | (1.18) | 2.37 |
Shareholders Equity (Total) |
24.17 | 2.54 | 3.58 | 3.63 | 13.27 | (1.18) | 2.37 |
Shareholders Equity and Liabilities (Total) |
31.61 | 2.81 | 5.16 | 5.88 | 15.04 | 1.53 | 3.02 |
Shares (Common) |
0.10 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Shares (Preferred) |
0.00 | — | — | — | — | — | — |
Shareholders Equity (Tangible) |
18.47 | 2.54 | 3.58 | 3.63 | 13.27 | (1.18) | 2.37 |
Net Debt |
(6.19) | (2.00) | (3.39) | (3.15) | (12.43) | 0.39 | (2.31) |
Total Debt |
6.45 | — | — | 0.37 | 0.55 | 1.43 | — |